10-Q: Pacira BioSciences Reports Q3 Profit, Strategic Growth

Pacira BioSciences, Inc. reported a return to net income in Q3 2025, driven by increased product sales and favorable legal outcomes, alongside strategic acquisitions and pipeline advancements.

Summary

• Pacira BioSciences, Inc. reported net income of $5.4 million for the three months ended September 30, 2025, a significant improvement from a net loss of $143.5 million in the prior year period.
• Total revenues increased by 6% to $179.5 million for the three months ended September 30, 2025, compared to $168.6 million in the same period last year.
• Gross margin improved by 4 percentage points to 81% for the three months ended September 30, 2025, primarily due to lower EXPAREL inventory reserves and improved ZILRETTA product costs.
• The company acquired the remaining 81% equity interest in GQ Bio Therapeutics GmbH in February 2025 for $30.6 million, gaining its novel high-capacity adenovirus (HCAd) platform and preclinical assets.
• A $300.0 million senior secured revolving credit facility was established in July 2025, used to repay the remaining $98.8 million of the Term Loan A Facility and its final interest payment of $0.1 million.
• The $202.5 million outstanding principal balance of the 0.750% Convertible Senior Notes due 2025 was repaid in cash upon maturity on August 1, 2025.
• A new share repurchase program for up to $300.0 million was approved in April 2025, with $100.4 million used to repurchase 3,932,106 shares during the nine months ended September 30, 2025.
• The company received a $28.3 million cash payment in July 2025, including $23.1 million in royalties and $5.2 million in statutory interest, following a favorable legal judgment against the Research Development Foundation (RDF).
• A settlement agreement was reached in April 2025 regarding patent infringement suits against eVenus ANDA Filers, granting them a license for volume-limited generic bupivacaine liposome injectable suspension starting early 2030 and unlimited quantity starting 2039, in exchange for a $7.0 million payment from Pacira.
• An impairment charge of $25.9 million was recognized for the ZILRETTA acquired in-process research and development (IPR&D) intangible asset for shoulder OA pain due to revised completion timelines.
• A reduction in force impacting 71 employees (8% of workforce) was instituted in July 2025, along with the decommissioning of a 45-liter EXPAREL manufacturing suite, expected to result in an annual reduction in operating expenses of approximately $13.0 million.
• A new U.S. Patent No. 12,370,142 for EXPAREL, claiming composition manufactured by an enhanced process, was issued in August 2025, expiring in July 2044.
• New data from the Phase 1 clinical trial for PCRX-201 (gene therapy for OA of the knee) demonstrated sustained efficacy for up to three years, with enrollment for Part A of the Phase 2 ASCEND study concluded.
• An exclusive worldwide license agreement was announced in November 2025 with AmacaThera, Inc. for AMT-143, a long-acting ropivacaine formulation, involving a $5.0 million upfront payment and potential future milestones/royalties.

Sentiment

Score: 7

Explanation: The company demonstrated a strong financial turnaround with positive net income and improved gross margins, driven by core product growth and favorable legal outcomes. Strategic acquisitions and pipeline advancements, particularly in gene therapy and new non-opioid options, position it for future growth. However, increased operating expenses, a decrease in cash, and new generic challenges for EXPAREL introduce some caution.

Positives

• Net income of $5.4 million for Q3 2025, a significant turnaround from a $143.5 million net loss in Q3 2024.
• Total revenues increased by 6% in Q3 2025 and 3% year-to-date, driven by strong EXPAREL and iovera sales.
• EXPAREL revenue grew 6% in Q3 2025 and 5% year-to-date, with a 9% increase in gross vial volume for the quarter.
• iovera net product sales increased by 14% in Q3 2025 and 5% year-to-date, driven by Smart Tip volume growth.
• Gross margin improved by 4 percentage points to 81% in Q3 2025 and 79% year-to-date, reflecting lower inventory reserves and improved ZILRETTA product costs.
• Successful acquisition of GQ Bio Therapeutics GmbH in February 2025, integrating the HCAd platform and preclinical assets.
• Favorable legal judgment against Research Development Foundation (RDF) resulted in a $28.3 million cash payment to Pacira and elimination of future EXPAREL royalties.
• Settlement of eVenus patent infringement suits provides clarity and a defined market entry for generic competition, avoiding prolonged litigation costs.
• Issuance of new U.S. Patent No. 12,370,142 for EXPAREL, extending patent protection until July 2044.
• Positive Phase 1 data for PCRX-201 showing sustained efficacy for up to three years and no impact from pre-existing neutralizing antibodies, with Phase 2 enrollment progressing.
• Strategic co-promotion agreement with Johnson & Johnson MedTech for ZILRETTA, expanding market reach into new physician specialties.
• Exclusive worldwide license agreement with AmacaThera for AMT-143, adding a promising non-opioid analgesic to the pipeline.
• Goodwill impairment of $163.2 million recorded in Q3 2024 was not repeated in Q3 2025, indicating stabilization of asset valuation.

Negatives

• ZILRETTA revenue decreased by 2% for the nine months ended September 30, 2025, primarily due to a 4% decrease in kit volume, impacted by sales force realignment.
• Research and development expenses increased significantly by 36% in Q3 2025 and 38% year-to-date, driven by clinical trial costs and personnel.
• Selling, general and administrative expenses increased by 23% in Q3 2025 and 25% year-to-date, due to investments in marketing, sales force expansion, and administrative departments.
• Net cash provided by operating activities decreased by $48.0 million to $108.3 million for the nine months ended September 30, 2025, compared to $156.3 million in the prior year.
• Cash and cash equivalents decreased from $276.8 million at December 31, 2024, to $147.6 million at September 30, 2025.
• An impairment of $25.9 million was recognized for the ZILRETTA acquired IPR&D intangible asset for shoulder OA pain, attributed to revised completion timelines for clinical trials and commercial availability.
• New Paragraph IV Certifications received in October 2025 from two Chinese generic drug manufacturers for EXPAREL, indicating new patent infringement challenges.
• Ongoing securities class action and shareholder derivative suit alleging false/misleading statements and breach of fiduciary duties concerning EXPAREL patents.
• The U.S. government shutdown since October 1, 2025, poses potential risks to FDA review timelines and CMS reimbursement, though no material impact has been experienced yet.

Risks

• Competition from larger companies and potential generic entrants, including new Paragraph IV certifications for EXPAREL from WhiteOak Group and Qilu Pharmaceutical.
• Reliance on revenue from three primary products (EXPAREL, ZILRETTA, iovera).
• Reliance on a limited number of wholesalers (three largest wholesalers accounted for 77% of Q3 2025 revenues).
• Reliance on a limited number of manufacturing sites and sole source suppliers, with active pharmaceutical ingredients for EXPAREL and ZILRETTA sourced from outside the U.S.
• Risks associated with new technological innovations and dependence on key personnel.
• Protection of proprietary technology and compliance with government regulations.
• Risks related to cybersecurity.
• Failure to realize anticipated benefits and synergies from the GQ Bio Therapeutics GmbH acquisition.
• Risks associated with acquisitions, such as integration difficulties, higher costs, or failure to achieve expected benefits.
• Impact of global economic conditions, including inflation, rising interest rates, and tariffs, on costs, patient demand, and supply chain.
• Potential for higher tariffs on pharmaceutical imports, including a proposed 100% tariff on branded/patented products unless manufactured in the U.S.
• Uncertainty and volatility in U.S. tariff and customs policy making it difficult to forecast costs and plan global supply chain.
• Potential adverse impact from a prolonged U.S. government shutdown on FDA regulatory reviews and CMS reimbursement.
• The outcome of ongoing legal proceedings, including the securities class action and shareholder derivative suit, which could result in unfavorable outcomes.
• The Research Development Foundation (RDF) has filed two notices of appeal regarding the legal judgment in Pacira's favor, potentially prolonging the dispute.
• The commercial opportunity for EXPAREL could be significantly harmed if competitors develop and commercialize alternative long-acting bupivacaine formulations not covered by Pacira's patents.
• Litigation to enforce or defend intellectual property rights is complex, expensive, time-consuming, and may divert management's attention.

Future Outlook

The company expects to continue pursuing expanded use of EXPAREL, ZILRETTA, and iovera, progress its earlier-stage product candidate pipeline, advance regulatory activities, invest in sales and marketing, expand manufacturing capacity, invest in products/businesses/technologies, and support legal matters. It anticipates that existing cash, investments, and product sales will cover operating expenses and capital requirements for the next 12 months. The company is on track to report results from a pre-specified interim analysis of the PCRX-201 Phase 2 ASCEND study before the end of 2026 and expects to initiate a Phase 2 program for AMT-143 in 2026. The workforce reduction is anticipated to lead to an annual reduction in operating expenses of approximately $13.0 million.

Management Comments

• Management believes the larger 200+ liter manufacturing suites provide ample capacity for meeting growing demand and improving gross margins for EXPAREL through a meaningfully more favorable cost structure and manufacturing yields versus the 45-liter batch process.
• The acquisition of GQ Bio allows the company to benefit from further developing PCRX-201, achieve cost savings from eliminated milestone and royalty payments, and establish a dedicated R&D engine for genetic medicine.
• The company intends to vigorously defend its intellectual property rights relating to EXPAREL against new generic challengers.

Industry Context

The biopharmaceutical industry continues to see innovation in pain management, with a growing focus on non-opioid therapies. Pacira's strategy aligns with this trend, leveraging its proprietary drug delivery technologies (pMVL, HCAd) and cryoanalgesia device (iovera) to address postsurgical pain and chronic conditions like osteoarthritis. The increasing prevalence of OA, affecting over 32.5 million adults in the U.S., provides a substantial market opportunity for ZILRETTA, iovera, and the gene therapy candidate PCRX-201. The company's partnerships with J&J MedTech and AmacaThera reflect a broader industry trend of strategic collaborations to expand market reach and diversify pipelines. However, the industry also faces challenges from generic competition and regulatory scrutiny, as evidenced by the Paragraph IV certifications and ongoing legal proceedings.

Comparison to Industry Standards

• The company's EXPAREL product, a long-acting local analgesic, competes in the postsurgical pain management market against traditional bupivacaine and other long-acting formulations. The issuance of a new patent extending protection to 2044 strengthens its competitive position against generic bupivacaine products, although new Paragraph IV challenges indicate ongoing competitive pressure.
• ZILRETTA, as the first and only extended-release, intra-articular injection for OA knee pain, offers a differentiated option compared to traditional immediate-release corticosteroids, hyaluronic acid, or platelet-rich plasma injections. The co-promotion agreement with Johnson & Johnson MedTech aims to expand its reach beyond orthopedic practices into broader physician specialties, a common strategy for market penetration in competitive therapeutic areas.
• iovera, a drug-free cryoanalgesia device, provides a non-pharmacological nerve block for pain control, including OA knee pain and chronic low back pain. Its demonstrated effectiveness in reducing opioid use post-TKA aligns with global efforts to reduce opioid dependence, positioning it favorably against other pain management modalities.
• PCRX-201, a gene therapy candidate for OA of the knee, targets a large prevalent disease with a novel HCAd vector platform. The sustained efficacy observed in Phase 1 data (up to 3 years) and the RMAT/ATMP designations suggest a potentially significant advancement compared to existing OA treatments, which typically offer shorter-term relief (3-6 months). The ability to potentially re-dose, despite pre-existing neutralizing antibodies, addresses a major challenge in gene therapy, setting a high bar for competitors in the gene therapy space.
• The acquisition of AmacaThera's AMT-143, a long-acting ropivacaine formulation, complements Pacira's existing portfolio by adding another non-opioid option for postsurgical pain, leveraging a different drug delivery platform (hydrogel) than EXPAREL's pMVL technology. This diversification of drug delivery mechanisms is a strategic move to capture a broader market segment.

Management Changes

Corporate Governance

Legal Proceedings

• MyoScience Milestone Litigation: Court ruled in favor of Pacira in January 2025, finding disputed milestones were not met. Fortis Advisors LLC agreed to pay Pacira $5.2 million for attorney fees, and a final judgment was entered in April 2025.
• eVenus Pharmaceutical Laboratories Litigations: Pacira settled patent infringement suits against eVenus ANDA Filers in April 2025. The settlement grants a license for volume-limited generic bupivacaine liposome injectable suspension starting early 2030, and an unlimited quantity starting 2039. Pacira paid the eVenus ANDA Filers $7.0 million.
• Paragraph IV Certification Notices: In October 2025, Pacira received two separate Paragraph IV Certifications from WhiteOak Group, Inc. and Qilu Pharmaceutical (Hainan) Co., Ltd., seeking authorization to market generic EXPAREL. Pacira is assessing these and intends to vigorously defend its intellectual property.
• Argentum Request for Ex Parte Reexamination of 495 Patent: The USPTO issued a Reexamination Certificate in August 2025, agreeing with Pacira's position after claim amendments, effectively upholding the patent against Argentum's challenge.
• Securities Class Action (Leandro Alvarez): Filed January 13, 2025, alleging materially false and misleading statements and/or concealed material adverse facts concerning EXPAREL patents. The case is in the pleadings stage.
• Shareholder Derivative Action (Young v. Lee, et al): Filed June 16, 2025, alleging certain officers and directors breached fiduciary duties by making materially false and misleading statements and/or concealing material adverse facts concerning EXPAREL patents. The case is in the pleadings stage.
• Research Development Foundation (RDF): U.S. District Court for the District of Nevada issued judgment in April 2025 in favor of Pacira, eliminating low single-digit royalties on EXPAREL. In June 2025, the court ordered RDF to repay Pacira $23.1 million in royalties plus $5.2 million in statutory interest. Pacira received a $28.3 million cash payment in July 2025. RDF filed two notices of appeal in May and September 2025, which are pending.

Stakeholder Impact

• Shareholders: Positive net income turnaround, share repurchase program, and favorable legal outcomes could positively impact shareholder value. However, increased operating expenses and new generic challenges for EXPAREL introduce uncertainty. Securities class action and shareholder derivative suit pose potential risks.
• Employees: A reduction in force impacted 71 employees (8% of the workforce) in July 2025, leading to termination benefits but also potential morale impacts. The GQ Bio acquisition brought new R&D talent. Stock incentive and inducement plans aim to retain and attract key personnel.
• Customers: Continued investment in EXPAREL, ZILRETTA, and iovera, along with new product candidates like PCRX-201 and AMT-143, aims to provide innovative non-opioid pain therapies. The co-promotion agreement with J&J MedTech is expected to expand ZILRETTA's reach to more physicians and patients.
• Suppliers: Reliance on a limited number of manufacturing sites and sole source suppliers, with active pharmaceutical ingredients sourced internationally, exposes the company to supply chain risks and potential tariff impacts.
• Creditors: The repayment of the 2025 Notes and the Term Loan A Facility, along with the establishment of a new Revolving Credit Facility, demonstrates active debt management and refinancing, which could be viewed positively by creditors.

Next Steps

• Continue to pursue expanded use of EXPAREL, ZILRETTA, and iovera in additional procedures.
• Progress earlier-stage product candidate pipeline, including PCRX-201 and other HCAd-based gene therapy programs.
• Advance regulatory activities for EXPAREL, ZILRETTA, iovera, PCRX-201, and other product candidates.
• Invest in sales and marketing resources for EXPAREL, ZILRETTA, and iovera.
• Expand and enhance manufacturing capacity for EXPAREL, ZILRETTA, and iovera.
• Invest in products, businesses, and technologies, including additional strategic investments.
• Support legal matters, including vigorously defending intellectual property rights related to EXPAREL against new Paragraph IV challenges.
• Report results from a pre-specified interim analysis of the PCRX-201 Phase 2 ASCEND study before the end of 2026.
• Initiate a Phase 2 program for AMT-143 in 2026.
• Continue to evaluate the impacts of the U.S. government shutdown on business and results of operations.
• Finalize the valuation of liabilities and tax analyses for the GQ Bio Acquisition, no later than one year after the acquisition date.

Key Dates

Recommendation

Pacira BioSciences has demonstrated a strong operational turnaround, achieving net income after significant losses in the prior year, driven by robust product sales growth and improved gross margins. Key strategic moves, including the GQ Bio acquisition, new patent protection for EXPAREL, and promising pipeline data for PCRX-201, indicate a positive long-term trajectory. The successful resolution of several legal disputes, particularly the RDF royalty repayment, provides a significant cash inflow and reduces future expenses. However, the company faces notable headwinds: a substantial increase in R&D and SG&A expenses, a decrease in overall cash, and new Paragraph IV challenges for EXPAREL, which could lead to future generic competition. The impairment of the ZILRETTA IPR&D asset also highlights development risks. Given the mix of strong operational performance and strategic advancements against ongoing competitive and cost pressures, a 'hold' recommendation is appropriate. Investors should monitor the outcomes of the new generic challenges, the progress of the pipeline, and the company's ability to manage its increasing operating expenses while maintaining revenue growth.

Keywords

Pacira BioSciences, PCRX, EXPAREL, ZILRETTA, iovera, non-opioid pain therapy, gene therapy, osteoarthritis, postsurgical pain, biopharmaceutical, SEC filing, 10-Q, financial results, patent litigation, drug delivery, HCAd platform, RMAT designation, AmacaThera, AMT-143, corporate governance, share repurchase